M&A Deal Summary

Stanley Capital Acquires Noden Pharma DAC

On September 9, 2020, private equity firm Stanley Capital acquired life science company Noden Pharma DAC from PDL BioPharma for 53M USD

Acquisition Highlights
  • This is Stanley Capital’s 1st transaction in the Life Science sector.
  • This is Stanley Capital’s largest (disclosed) transaction.
  • This is Stanley Capital’s 1st transaction in Ireland.

M&A Deal Summary
Date 2020-09-09
Target Noden Pharma DAC
Sector Life Science
Buyer(s) Stanley Capital
Sellers(s) PDL BioPharma
Deal Type Divestiture
Deal Value 53M USD

Target

Noden Pharma DAC

Dublin, Ireland
Noden Pharma DAC is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market, and sell Tekturna® and Tekturna HCT (or Rasilez and Rasilez HTC outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. In March 2019, Noden announced the U.S commercial launch of an authorized generic form of Tekturna, aliskiren hemifumarate 150 mg, and 300 mg tablets with the same drug formulation as Tekturna. Noden Pharma DAC is headquartered in Dublin, Ireland.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Stanley Capital

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2019
Size Small
Type Sector Focused
DESCRIPTION

Stanley Capital is a private equity partnership that pursues healthcare and technology investments. The Firm targets businesses valued from $250 million to $2.5 billion with defensible business models and opportunities for growth. Stanley Capital was formed in 2019 and is headquartered in London.

DEAL STATS #
Overall 1 of 4
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 1
Country (Ireland) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-01 Qinecsa Solutions

London, United Kingdom

Qinecsa Solutions is a global provider of pharmacovigilance software and services. Qinecsa Solutions is based in London, United Kingdom.

Buy -

Seller(S) 1

SELLER

PDL BioPharma

Incline Village, Nevada, United States
Category Company
Founded 1986
Sector Life Science
Employees109
Revenue 55M USD (2019)
DESCRIPTION

PDL BioPharma is a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL BioPharma was founded in 1986 and is based in Incline Village, Nevada.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Ireland) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-10-26 Neos Therapeutics

Grand Prairie, Texas, United Kingdom

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform.

Buy -
Mergr

Product

Company

Legal